8-K - Imunon, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Imunon reported a 2025 net loss of $14.5 million and provided positive final Phase 2 survival data for IMNN-001, showing a median overall survival increase of 14.7 months.

Key Takeaways

1Final Phase 2 OVATION 2 data showed a median 14.7-month overall survival benefit for IMNN-001 plus standard of care versus standard of care alone.

2Net loss for 2025 decreased to $14.5 million from $18.6 million in 2024, with operating expenses down 23%.

3Enrollment in the pivotal Phase 3 OVATION 3 study is proceeding ahead of plan.

4Cash and cash equivalents totaled $8.8 million as of December 31, 2025.

5The Company completed a $7.0 million registered direct offering on December 31, 2025.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

Results of Operations and Financial Condition.** On March 31, 2026, Imunon, Inc. issued a press release reporting its financial results for the year ended Decem

Financial Results

9.01

Financial Statements and Exhibits.** (d) Exhibits. | Exhibit No. | | Description | |---|---|---| | | | | | 99.1 | | Press Release dated March 31, 2026 | | 104 |

Exhibits Only

Source Document

Results of Operations

Year Ended December 31, 2025

Metric	Value	Basis	Prior Period
Net Loss	$-14.50	GAAP	$-18.60
Net Loss Per Share	$-6.83	GAAP	$-16.94
Operating Expenses	$14.70	GAAP	$19.27
Research and Development Expenses	$7.80	GAAP	$11.64
General and Administrative Expenses	$6.90	GAAP	$7.50

Exhibits (2)

8-K

99.1

EX-99.1